Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: a double blind prospective randomized controlled trial

Tom Schepens, Koen Janssens, Sabine Maes, Davina Wildemeersch, Jurryt Vellinga, Philippe G Jorens, Vera Saldien, Tom Schepens, Koen Janssens, Sabine Maes, Davina Wildemeersch, Jurryt Vellinga, Philippe G Jorens, Vera Saldien

Abstract

Background: The use of neostigmine after neuromuscular blockade (NMB) has been associated with postoperative respiratory complications. In previous studies, we found lower diaphragmatic activity after neostigmine reversal of NMB, compared to sugammadex. It is still unclear whether the adequate use of neostigmine guarantees normal respiratory muscle function after NMB. In this study, we wanted to assess the effect of commonly used degrees of NMB and their possible reversal strategies on respiratory muscle activity after the return of normal neuromuscular transmission.

Methods: This is a randomized, controlled, parallel-group, single-centre, double-blind study in patients scheduled for intracranial surgery at a tertiary academic hospital in Belgium. All participants received target controlled propofol/remifentanil anesthesia and were randomized into one of five groups, receiving either a shallow NMB with no reversal (shallow/saline), a shallow NMB with sugammadex reversal (shallow/sugammadex), a moderate NMB with neostigmine reversal (moderate/neostigmine), a moderate NMB with sugammadex reversal (moderate/sugammadex), or a deep NMB with sugammadex reversal (deep/sugammadex). Primary and secondary outcome parameters were diaphragm and intercostal electromyographic (EMG) activity at the moment of resumed spontaneous breathing activity, defined as a maximal interval of 10 min after the first spontaneous breath.

Results: For the five groups, a total of 55 patients could be included in the final analysis. Median time of spontaneous breathing analyzed was 5 min (IQR 3-9.5 min). Both the moderate/sugammadex and the moderate/neostigmine groups had lower levels of diaphragm EMG compared to the shallow/sugammadex group. The moderate/neostigmine group had lower levels of intercostal EMG activity compared to the shallow/saline group.

Conclusions: In this study, the depth of neuromuscular blockade and type of reversal strategy impacts respiratory muscle activity at the moment of resumed spontaneous breathing and recovery of neuromuscular blockade. Both groups that received moderate NMB had lower levels of diaphragm EMG, compared to the shallow NMB group with sugammadex reversal. Compared to the shallow NMB group with no reversal, the moderate NMB with neostigmine reversal group had lower intercostal EMG activity.

Trial registration: Clinicaltrials.gov NCT01962298 on October 9, 2013 and EudraCT 2013-001926-25 on October 10, 2013.

Keywords: Neostigmine; Neuromuscular blockade; Neuromuscular blocking agents; Respiratory outcome; Sugammadex.

Conflict of interest statement

TS and VS have received research grants from Merck & Co / MSD. TS has received travel funding from Merck & Co / MSD. All other authors have no conflicts of interest related to this article.

Figures

Fig. 1
Fig. 1
Sample of unfiltered EMG data. Top curve (“P3”) shows the pressure/flow signal, indicating inspiratory and expiratory flow. The following 5 curves show the raw EMG per set of leads for the diaphragm and the intercostal muscles. Bottom 5 show amplitudes of these raw signals. To obtain these data, electrodes are positioned bilaterally on the chest wall, on the mid-axillary and midclavicular lines just below the costal margins. The intercostal electrodes are positioned on the mid-clavicular line as well. Changes in electrical currents are measured in between a pair of electrodes, with a reference electrode positioned on the sternum. Currents flowing from the two right and left sided electrodes were labeled aR Dia and aL Dia, those in between the electrodes on the midclavicular line aF Dia, and those placed laterally aD Dia. The final data combined the signals from left and right
Fig. 2
Fig. 2
Simplified CONSORT flowchart. Legend: NMB: neuromuscular block

References

    1. Hunter JM. Reversal of residual neuromuscular block: complications associated with perioperative management of muscle relaxation. Br J of Anaesth. 2017;119(Suppl 1):i53–i62. doi: 10.1093/bja/aex318.
    1. Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2018;73:631–641. doi: 10.1111/anae.14160.
    1. Grosse-Sundrup M, Henneman JP, Sandberg WS, Bateman BT, Uribe JV, Nguyen NT, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329. doi: 10.1136/bmj.e6329.
    1. Meyer MJ, Bateman BT, Kurth T, Eikermann M. Neostigmine reversal doesn't improve postoperative respiratory safety. BMJ. 2013;346:f1460. doi: 10.1136/bmj.f1460.
    1. Sasaki N, Meyer MJ, Malviya SA, Stanislaus AB, MacDonald T, Doran ME, et al. Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes. Anesthesiology. 2014;121:959–968. doi: 10.1097/ALN.0000000000000440.
    1. Murphy Glenn S., Szokol Joseph W., Avram Michael J., Greenberg Steven B., Shear Torin D., Deshur Mark A., Benson Jessica, Newmark Rebecca L., Maher Colleen E. Neostigmine Administration after Spontaneous Recovery to a Train-of-Four Ratio of 0.9 to 1.0. Anesthesiology. 2018;128(1):27–37. doi: 10.1097/ALN.0000000000001893.
    1. McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology. 2015;122:1201–1213. doi: 10.1097/ALN.0000000000000674.
    1. Fleming NW, Henderson TR, Dretchen KL. Mechanisms of respiratory failure produced by neostigmine and diisopropyl fluorophosphate. Eur J Pharmacol. 1991;195:85–91. doi: 10.1016/0014-2999(91)90384-3.
    1. Schepens T, Cammu G, Saldien V, De Neve N, Jorens PG, Foubert L, et al. Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium. Eur J Anaesthesiol. 2015;32:49–57. doi: 10.1097/EJA.0000000000000140.
    1. Cammu G, Schepens T, De Neve N, Wildemeersch D, Foubert L, Jorens PG. Diaphragmatic and intercostal electromyographic activity during neostigmine, sugammadex and neostigmine-sugammadex-enhanced recovery after neuromuscular blockade: a randomised controlled volunteer study. Eur J Anaesthesiol. 2017;34:8–15. doi: 10.1097/EJA.0000000000000543.
    1. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009;103:115–129. doi: 10.1093/bja/aep093.
    1. Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade. Eur J Anaesthesiol. 2014;31:423–429. doi: 10.1097/EJA.0000000000000010.
    1. Kirmeier E, Eriksson LI, Lewald H, Jonsson Fagerlund M, Hoeft A, Hollman M, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7:129–140. doi: 10.1016/S2213-2600(18)30294-7.
    1. Feldman S, Karalliede L. Drug interactions with neuromuscular blockers. Drug Saf. 1996;15:261–273. doi: 10.2165/00002018-199615040-00004.
    1. McLean Duncan J., Diaz-Gil Daniel, Farhan Hassan N., Ladha Karim S., Kurth Tobias, Eikermann Matthias. Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications. Anesthesiology. 2015;122(6):1201–1213. doi: 10.1097/ALN.0000000000000674.
    1. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130–137. doi: 10.1213/ane.0b013e31816d1268.
    1. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120–128. doi: 10.1213/ANE.0b013e3181da832d.
    1. Grabitz Stephanie D., Rajaratnam Nishan, Chhagani Khushi, Thevathasan Tharusan, Teja Bijan J., Deng Hao, Eikermann Matthias, Kelly Barry J. The Effects of Postoperative Residual Neuromuscular Blockade on Hospital Costs and Intensive Care Unit Admission. Anesthesia & Analgesia. 2019;128(6):1129–1136. doi: 10.1213/ANE.0000000000004028.
    1. Kopman AF, Naguib M. Neostigmine: you Can't have it both ways. Anesthesiology. 2015;123:231–233. doi: 10.1097/ALN.0000000000000678.
    1. Eikermann M, Gerwig M, Hasselmann C, Fiedler G, Peters J. Impaired neuromuscular transmission after recovery of the train-of-four ratio. Acta Anaesthesiol Scand. 2007;51:226–234. doi: 10.1111/j.1399-6576.2006.01228.x.
    1. Karayiannakis AJ, Makri GG, Mantzioka A, Karousos D, Karatzas G. Postoperative pulmonary function after laparoscopic and open cholecystectomy. Br J Anaesth. 1996;77:448–452. doi: 10.1093/bja/77.4.448.
    1. McCool FD, Tzelepis GE. Dysfunction of the diaphragm. N Engl J Med. 2012;366:932–942. doi: 10.1056/NEJMra1007236.

Source: PubMed

3
Iratkozz fel